Katarina Cepo

Real-World Early Treatment with Room Temperature–Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses

G. Benson, H. Chambost, P. Eshghi, 2017, TH Open.

Surgeries and Diagnostic Procedures in Hemophilia Patients on Concizumab Prophylaxis: Results from the Phase 2 Explorer4 and Explorer5 Trials

G. Benson, H. Eichler, T. Matsushita, 2021, Blood.

Concizumab Subcutaneous Prophylaxis Improves Health-Related Quality-of-Life Measures in Patients with Congenital Hemophilia with Inhibitors: Phase 2 Trial Results

T. Porstmann, X. Y. Lee, Katarina Cepo, 2019, Blood.

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial

V. Jiménez‐Yuste, C. Hollensen, G. Castaman, 2019, Blood.

Risk Mitigation Strategy for Concizumab Clinical Trials after Pause Due to Non-Fatal Thrombotic Events

Trine Høyer Rose, S. Seremetis, S. Tamer, 2020 .

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

J. Astermark, J. Oldenburg, G. Benson, 2019, Blood.